The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The bicyclam AMD3100 story
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y., Matsushima, K., Yoshida, N., Nishikawa, S.-I., et al. (1998) · Nature · doi:10.1038/31261 · Cited by 1,525
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., et al. (2002) · Nature Immunology · doi:10.1038/ni813 · Cited by 1,332
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, G. A., Schols, D., Lin, S. W., Esté, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., DeClercq, E., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-072 · Cited by 760
Self-citationInhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554
Hendrix, C. W., Flexner, C., MacFarland, R. T., Giandomenico, C., Fuchs, E. J., Redpath, E., Bridger, G., & Henson, G. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1667-1673.2000 · Cited by 504
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton, C. J., Wilson, J. L., Scott, K. A., Stamp, G., Wilbanks, G. D., Fricker, S. P., Bridger, G. J., & Balkwill, F. R. (2002) · PubMed · Cited by 471
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4
Hatse, S., Princen, K., Bridger, G., De Clercq, E., & Schols, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03143-5 · Cited by 448
Self-citation
Cited by
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology
Haas, K. L., & Franz, K. J. (2009) · Chemical Reviews · doi:10.1021/cr900134a · Cited by 984
Broxmeyer, H. E., Orschell, C. M., Clapp, D. W., Hangoc, G., Cooper, S., Plett, P. A., Liles, W. C., Li, X., Graham-Evans, B., Campbell, T. B., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041385 · Cited by 970
Antiviral drugs in current clinical use
De Clercq, E. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 947
Self-citationKojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., Onder, T. T., Wang, Z. C., Richardson, A. L., Weinberg, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013805107 · Cited by 848
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
The significance of cancer cell expression of the chemokine receptor CXCR4
Balkwill, F. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.003 · Cited by 758
CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer
Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., Piwnica-Worms, D., & Luker, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1844 · Cited by 715
Allosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
The Intricate Role of CXCR4 in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 672
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627
“19), has been described [23] but this compound is not orally bioavailable.”
BackgroundUsing coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation
Viola, A., & Luster, A. D. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.121806.154841 · Cited by 583
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
Burger, J. A., & Peled, A. (2009) · Leukemia · doi:10.1038/leu.2008.299 · Cited by 462
Arylglyoxals in Synthesis of Heterocyclic Compounds
Eftekhari-Sis, B., Zirak, M., & Akbari, A. (2013) · Chemical Reviews · doi:10.1021/cr300176g · Cited by 453
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 395
Bowie, M. B., McKnight, K. D., Kent, D. G., McCaffrey, L., Hoodless, P. A., & Eaves, C. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28310 · Cited by 380
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 370
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
Self-citationBone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
β-Hairpin Peptidomimetics: Design, Structures and Biological Activities
Robinson, J. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar700259k · Cited by 321
Devine, S. M., Vij, R., Rettig, M., Todt, L., McGlauchlen, K., Fisher, N., Devine, H., Link, D. C., Calandra, G., Bridger, G., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130179 · Cited by 308
Kojima, T., Hirota, Y., Ema, M., Takahashi, S., Miyoshi, I., Okano, H., & Sawamoto, K. (2010) · Stem Cells · doi:10.1002/stem.306 · Cited by 308
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Esté, J. A., & Telenti, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61052-6 · Cited by 287
Chemokines: Integrators of Pain and Inflammation
White, F. A., Bhangoo, S. K., & Miller, R. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1852 · Cited by 280
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
De Clercq, E. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.014 · Cited by 277
Self-citationTargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
Dubrovska, A., Cojoc, M., Peitzsch, Trautmann, F., Polishchuk, & Telegeev (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36109 · Cited by 254
Chu, C.-Y., Cha, S.-T., Chang, C.-C., Hsiao, C.-H., Tan, C.-T., Lu, Y.-C., Jee, S.-H., & Kuo, M.-L. (2007) · Oncogene · doi:10.1038/sj.onc.1210040 · Cited by 78
McCarthy, C. W., Goldman, J., & Frost, M. C. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b12548 · Cited by 30
Metadata
- Authors
- De Clercq, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-07
- Volume
- 2
- Issue
- 7
- Pages
- 581-587
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1548997088
- Cited by
- 460
- References
- 31
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.